SUZHOU, China , Aug. 23, 2024 /PRNewswire/ -- Abogen Biosciences ("Abogen" or the "Company") announced a publication titled "Efficient circularization of protein-encoding RNAs via a novel cis -splicing system " in Nucleic Acids Research . In the article, Abogen has revealed a highly efficient RNA circularization cis-splicing system (referred to as the "Cis-System") which enables the production of circular RNA ("circRNA") with significantly extended protein expression, reduced innate immune activation, and flexible splice site design that offers substantial market potential.
In recent years, circular RNA technology has gained significant attention from the biopharmaceutical industry, several circular RNA start-up companies raised a total of over 1 billion dollars in financing. Among the most notable are Flagship-incubated Sail Biomedicines (formed through the merger of Laronde and Senda Biosciences), which has raised nearly $800 million , and Orna Therapeutics, founded by MIT Professor Daniel Anderson , secured over $300 million in funding and recently acquired ReNAgade Therapeutics to accelerate its clinical development. Abogen's Cis-System-based circRNA not only has global IP, but also improves over PIE System The conventional technology for circRNA synthesis is the PIE method (Permuted Introns and Exons), patented by Orna and other companies.
However, the Cis-System not only circumvents the patent restrictions by the PIE system, but also simplifies the circularization proce.